Why the study?
It was unknown whether sacubitril/valsartan is more effective than a proven ACE inhibitor in preventing the development of HF and cardiovascular death following AMI.
Does sacubitril/valsartan prevent development of heart failure and cardiovascular death compared to an ACE inhibitor in patients following acute myocardial infarction?
Does sacubitril/valsartan prevent development of heart failure and cardiovascular death compared to an ACE inhibitor in patients following acute myocardial infarction?
The PARADISE-MI trial is designed to evaluate whether sacubitril/valsartan is superior to an ACE inhibitor in preventing heart failure and cardiovascular death after acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Leaves open sacubitril/valsartan superiority post-MI versus ACE inhibitors; randomized results needed before any practice change.
Baseline therapies in PARADISE-MI reflect advances in contemporary evidence-based care. With enrollment complete PARADISE-MI is poised to determine whether sacubitril/valsartan is more effective than a proven ACE inhibitor in preventing development of HF and cardiovascular death following AMI.
No takes yet. Share an insight, caveat, or question.
Jering et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: